Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accounts Payables (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Accounts Payables data on record, last reported at $11.3 million in Q2 2025.

  • For Q2 2025, Accounts Payables changed N/A year-over-year to $11.3 million; the TTM value through Jun 2025 reached $11.3 million, changed N/A, while the annual FY2024 figure was $21.5 million, 227.87% up from the prior year.
  • Accounts Payables reached $11.3 million in Q2 2025 per CRNX's latest filing, down from $21.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $21.5 million in Q4 2024 and bottomed at $4.8 million in Q2 2023.
  • Average Accounts Payables over 5 years is $9.7 million, with a median of $7.1 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: crashed 71.72% in 2023, then surged 227.87% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $8.5 million in 2021, then dropped by 18.72% to $6.9 million in 2022, then dropped by 4.87% to $6.5 million in 2023, then soared by 227.87% to $21.5 million in 2024, then crashed by 47.25% to $11.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $11.3 million in Q2 2025, $21.5 million in Q4 2024, and $4.9 million in Q3 2024.